Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy (Q45888990)

17 December 2017

title

Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy (English)

1 reference

17 December 2017

0 references

Jian Chen

1

1 reference

17 December 2017

Qi Wu

2

1 reference

17 December 2017

Pingar Yang

3

1 reference

17 December 2017

Hui-Chen Hsu

4

1 reference

17 December 2017

John D Mountz

5

1 reference

17 December 2017

publication date

1 February 2006

1 reference

17 December 2017

published in

Molecular Therapy

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

260-269

1 reference

17 December 2017

Phenotypic analysis of antigen-specific T lymphocytes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

The source of early IFN-gamma that plays a role in Th1 priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Cytokine-specific ELISPOT assay. Single cell analysis of IL-2, IL-4 and IL-6 producing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

The molecular basis of haemophilia A and B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Adeno-associated virus-mediated gene transfer for hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

CD4 T cell-dependent CD8 T cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Mapping of genes that control the antibody response to human factor IX in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Environmental and genetic factors influencing inhibitor development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

SYFPEITHI: database for MHC ligands and peptide motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Chemistry of peptides associated with MHC class I and class II molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

AAV-mediated gene transfer for treatment of hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Genetic analysis of the antibody response to AAV2 and factor IX

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.10.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2005.10.006

1 reference

17 December 2017

PubMed ID

16324888

1 reference

17 December 2017